A Randomized, Double-Blind Clinical Trial of a 3-Week Course of Doxycycline plus Albendazole and Ivermectin for the Treatment of Wuchereria bancrofti Infection
Open Access
- 15 April 2006
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 42 (8) , 1081-1089
- https://doi.org/10.1086/501351
Abstract
Background. Eight- and 6-week courses of doxycycline are superior to standard treatment of bancroftian filariasis. Standard treatment (albendazole plus ivermectin) is associated with adverse reactions. We assessed whether a shorter (i.e, 3-week) course of doxycycline with standard treatment would show superior efficacy to standard treatment alone and reduce the incidence of adverse reactions. Methods. A total of 44 adults from Ghana were recruited in January 2003: 20 received doxycycline (200 mg/day) for 3 weeks, and 24 received matching placebo. Participants received albendazole (400 mg) and ivermectin (150 µg/kg) at month 4, and adverse reactions were assessed 48 h later. Treatment efficacy was evaluated at months 4, 12, and 24. Results. The microfilariae level was significantly reduced after receipt of doxycycline treatment at months 4 (P = .017), 12 (P = .001), and 24 (P = .005). The microfilariae level was only significantly reduced at month 12 in the placebo group (P = .041). At all follow-up points, the microfilariae level was significantly lower in the doxycycline group. Adverse reactions to standard antifilarial treatment were similar in frequency between the doxycycline group (in 7 of 11 subjects) and the placebo group (in 13 of 17 subjects). Moderate reactions only occurred in the placebo group (in 3 of 17 subjects). Severity of adverse reaction was associated with microfilaremia (P = .037), Wolbachia bacteria in plasma (P = .048), and proinflammatory cytokines in plasma (P = .019). Adult parasite viability was not significantly different between doxycycline and placebo groups at months 12 or 24. Conclusions. Treatment with doxycycline for 3 weeks is more effective in inducing a long-term amicrofilaremia than is standard treatment alone, but it is ineffective at inducing curative effects. Inflammatory reactions to antifilarial treatment are associated with levels of microfilariae and Wolbachia endosymbionts released into plasma.Keywords
This publication has 18 references indexed in Scilit:
- Population dynamics of Wolbachia bacterial endosymbionts in Brugia malayiMolecular and Biochemical Parasitology, 2004
- Doxycycline as a novel strategy against bancroftian filariasis?depletion of Wolbachia endosymbionts from Wuchereria bancrofti and stop of microfilaria productionMedical Microbiology and Immunology, 2003
- Wolbachia in the Inflammatory Pathogenesis of Human FilariasisAnnals of the New York Academy of Sciences, 2003
- Bacterial Endosymbionts ofOnchocerca volvulusin the Pathogenesis of Posttreatment ReactionsThe Journal of Infectious Diseases, 2002
- Editorial: The Global Programme to Eliminate Lymphatic FilariasisTropical Medicine & International Health, 2000
- Strong Association of Interleukin‐6 and Lipopolysaccharide‐Binding Protein with Severity of Adverse Reactions after Diethylcarbamazine Treatment of Microfilaremic PatientsThe Journal of Infectious Diseases, 2000
- Tetracycline therapy targets intracellular bacteria in the filarial nematode Litomosoides sigmodontis and results in filarial infertilityJournal of Clinical Investigation, 1999
- Assessment of the efficacy of diethylcarbamazine on adult Wuchereria bancrofti in vivoTransactions of the Royal Society of Tropical Medicine and Hygiene, 1997
- Interleukin-6 and Tumor Necrosis Factor in the Pathogenesis of Adverse Reactions after Treatment of Lymphatic Filariasis and OnchocerciasisThe Journal of Infectious Diseases, 1994
- Ocular findings in a double-blind study of ivermectin versus diethylcarbamazine versus placebo in the treatment of onchocerciasis.British Journal of Ophthalmology, 1987